SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BioVie Reports Symptom Improvement Trend in Phase 2 Long COVID Trial

BioVie said its Bezisterim trial showed a trend toward symptom improvement. The supplied report is truncated and provides no further trial details.

BIVI

Related stories